Company intelligence / Profile preview

Capital Plus

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

CapitalBio Technology has launched multiple commercial molecular detection products for hereditary disease, infectious disease, and cancer, including CE-IVD certified SARS-CoV-2 integrated microfluidic chip systems. Its biochip products have twice won China’s National Technology Invention Award (second prize).

Therapeutic areas: OncologyInfectious DiseasesOtherRare Diseases
Modalities: Medical deviceMolecular diagnosticsBiochipNext-generation sequencing
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Capital Plus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Capital Plus.

Explore the full profile